|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials显示文摘 | Carsten Bokemeyer Eric Van Cutsem Philippe Rougier Fortunato Ciardiello Steffen Heeger Michael Schlichting Ilhan Celik Claus-Henning K?hne | 2012 | European Journal of Cancer2012，，10： | 5 |
| 2 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: Special situations显示文摘 | Gert Van Assche Axel Dignass Bernd Bokemeyer Silvio Danese Paolo Gionchetti Gabriele Moser Laurent Beaugerie Fernando Gomollón Winfried H?user Klaus Herrlinger Bas Oldenburg Julian Panes Francisco Portela Gerhard Rogler Jürgen Stein Herbert Tilg Simon Tra | 2012 | Journal of Crohn’s and Colitis2012，，： | 4 |
| 3 | HER-2 amplification is highly homogenous in gastric cancer显示文摘 | Andreas H. Marx Lars Tharun Johanna Muth Ana-Maria Dancau Ronald Simon Emre Yekebas Jussuf T. Kaifi Martina Mirlacher Tim H. Brümmendorf Carsten Bokemeyer Jakob R. Izbicki Guido Sauter | 2009 | Human Pathology2009，，6： | 3 |
| 4 | Aktualisierte Leitlinie zur Diagnostik und Therapie der Colitis ulcerosa 2011 – Ergebnisse einer Evidenzbasierten Konsensuskonferenz显示文摘 | A. Dignass J. Prei? D. Aust F. Autschbach A. Ballauff G. Barretton B. Bokemeyer S. Fichtner-Feigl S. Hagel K. Herrlinger G. Jantschek A. Kroesen W. Kruis T. Kucharzik J. Langhorst M. Reinshagen G. Rogler D. Schleiermacher C. Schmidt S. Schreiber H. Schulz | 2011 | Z Gastroenterol2011，，09： | 2 |
| 5 | Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines显示文摘 | Andreas Harstrick Carsten Bokemeyer Martin Scharnofkse Gunnar Hapke Dagmar Reile Hans-Joachim Schmoll | 1993 | Cancer Chemotherapy and Pharmacology1993，，1： | 2 |
| 6 | Parameters of a severe disease course in ulcerative colitis显示文摘AIM:To detect high risk patients with a progressive disease course of ulcerative colitis(UC) requiring immunosuppressive therapy(IT).METHODS:A retrospective,multicenter analysis of 262 UC patients from eight German tertiary inflammatory bowel disease centres was performed.Patients were divided into two groups depending on the patients need to initiate immunosuppressive therapy in the disease course.A comparison between the two groups was made with regard to demographics,clinical and laboratory parameters obtained within three months after UC diagnosis and the response to first medical therapy.Using this data,a prognostic model was established to predict the individual patients probability of requiring an immunosuppressive therapy.RESULTS:In 104(39.7%) out of 262 patients,UC therapy required an immunosuppressive treatment.Patients in this group were significantly younger at time of diagnosis(HR = 0.981 ± 0.014 per year,P = 0.009),and required significantly more often a hospitalisation(HR = 2.5 ± 1.0,P < 0.001) and a systemic corticosteroid therapy at disease onset(HR = 2.4 ± 0.8,P < 0.001),respectively.Response to steroid treatment was significantly different between the two groups of patients(HR = 5.2 ± 3.9 to 50.8 ± 35.6 compared to no steroids,P = 0.016 to P < 0.001).Furthermore,in the IT group an extended disease(HR = 3.5 ± 2.4 to 6.1 ± 4.0 compared to proctitis,P = 0.007 to P = 0.001),anemia(HR = 2.2 ± 0.8,P < 0.001),thrombocytosis(HR = 1.9 ± 1.8,P = 0.009),elevated C-reactive protein(CRP)(HR = 2.1 ± 0.9,P < 0.001),and extraintestinal manifestations in the course of disease(HR = 2.6 ± 1.1,P = 0.004) were observed.Six simple clinical items were used to establish a prognostic model to predict the individual risk requiring an IT.This probability ranges from less than 2% up to 100% after 5 years.Using this,the necessity of an immunosuppressive therapy can be predicted in 60% of patients.Our model can determine the need for an immunosuppressive drug therapy or if a 'watch and wait' approach is reasonable already early in the treatment course of UC.CONCLUSION:Using six simple clinical parameters,we can estimate the patients individual risk of developing a progressive disease course. | Andreas Stallmach Luisa Nickel Thomas Lehmann Bernd Bokemeyer Martin Bürger Dietrich Hüppe Wolfgang Kruis Susanna Nikolaus Jan C Preiss Andreas Sturm Niels Teich Carsten Schmidt | 2014 | World Journal of Gastroenterology2014，20，35： | 2 |
| 7 | Fluorouracil,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko I Makhson A | | Journal of Clinical Oncology0，，： | 2 |
| 8 | The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients显示文摘 | Heinz Ludwig Simon Van Belle Peter Barrett-Lee Gunnar Birgeg?rd Carsten Bokemeyer Pere Gascón Paris Kosmidis Maciej Krzakowski Johan Nortier Patrizia Olmi Maurice Schneider Dirk Schrijvers | 2004 | European Journal of Cancer2004，，15： | 2 |
| 9 | Hepatitis C virus infection and the brain显示文摘 | Karin Weissenborn Anita B. Tryc Meike Heeren Hans Worthmann Henning Pflugrad Georg Berding Martin Bokemeyer Hans L. Tillmann Annemarie Goldbecker | 2009 | Metabolic Brain Disease2009，，1： | 2 |
| 10 | KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab:The OPUS experience显示文摘 | Bokemeyer C Bondarenko I Hartmann JT | 2008 | J Clin Oncol2008，26，5： | 1 |
| 11 | Monoaminergic neu- rotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment显示文摘 | Weissenborn K Ennen JC Bokemeyer M | 2006 | GUT2006，55，11： | 1 |
| 12 | Fluorouraci,leucovorin,and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko L | 2008 | J Clin Oncol2008，27，6： | 1 |
| 13 | Cetuximab plus 5- FU/FA/oxaliplutin (FOLFOX-4) versus FOLFOX-4 in the first-line treaanent of metastatic colorectal cancer (mCRC) : OPUS, a randomized phase II study显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2007 | J Clin Oncol2007，，： | 1 |
| 14 | Fluorouracil, leu- covorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer 显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2009 | J Clin Oncol2009，27，5： | 1 |
| 15 | KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer with FOLFOX with or without cetuximab显示文摘 | Bokemeyer C Bondarenko I Hartmann JT | 2008 | J Clin Oncol2008，26，： | 1 |
| 16 | Fluoro- uracil, leucovorin, and oxaliplatin with and without ce- tuximab in the first-line treatment of metastatic colorectal cancer显示文摘 | Bokemeyer C Bondarenko I Makhson A | 2009 | J Clin Oncol2009，27，5： | 1 |
| 17 | Long-term g- ondai toxicity after therapy for Hodgkins and non-Hodgkin, s iymphoma 显示文摘 | BOKEMEYER C SCHM H J VANRHEE J | 1994 | Ann Hemato1994，68，3： | 1 |
| 18 | Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease显示文摘 | Rayko Evstatiev Olga Alexeeva Bernd Bokemeyer Ivan Chopey Marcel Felder Maja Gudehus Tariq Iqbal Igor Khalif Philippe Marteau Jürgen Stein Christoph Gasche | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 1 |
| 19 | Extragonadal germ cell tumors:Relationt to testicular neoplasia and management options显示文摘 | Bokemeyer C Hartmann JT | 2003 | APMIS2003，111，1： | 1 |
| 20 | KRAS status and efficacy of first- line treatments of patients with metastatic colorectal cancer (mCRC) with FOL- FOX with or without cetuximab: the OPUS experience显示文摘 | Bokemeyer C Bondarenko I Hartmann J T De Braud F G Volovat C Nippgen J | 2008 | J Clin Oncol2008，2620，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员